As we welcome another World Hepatitis Day, the global response to eliminate viral hepatitis as a public threat is accelerating. Viral hepatitis, consisting of hepatitis B (HBV) and hepatitis C (HCV), affects more than 320 million people worldwide, with 90 percent of...
Amsterdam – A breakthrough pricing agreement will significantly reduce the cost of diagnostic testing for HIV/AIDS, hepatitis and cervical cancer for millions of people in low- and middle-income countries. Diagnostic testing improves patient care, helps prevent the...
We are delighted to announce the joint launch of a partnership to speed up development and introduction of optimized pediatric formulations of dolutegravir for children living with HIV in resource-limited settings. The new initiative includes an incentive program and...
In Vietnam, a million people are infected with Hepatitis C (HCV). Without treatment, HCV can cause cirrhosis, liver cancer and even death. While no vaccines exist to prevent HCV, the virus is easily treated with directly-acting antivirals (DAAs). In 2017, CHAI worked...
Introducing the second edition of CHAI’s HIV Mid-Year Market Memo, an informational brief that covers the latest trends in the HIV space in low- and middle-income countries (LMICs) since the publication of CHAI’s annual ARV Market Report in September 2017. See the HIV...
